These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 18357351)

  • 21. The non-invasive diagnosis of precancerous changes of stomach mucosa.
    Pasechnikov VD; Chukov SZ; Kotelevets SM; Mostovov AN; Polyakova MB; Mernova VP
    Rocz Akad Med Bialymst; 2004; 49():66-71. PubMed ID: 15631316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation of serum pepsinogen level and gastric mucosal changes of residents in the high incidence area of gastric cancer].
    Zhang XH; Huang B; Wang JL; Li YH; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):507-11. PubMed ID: 17147114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of serum pepsinogen with atrophic body gastritis in Costa Rica.
    Sierra R; Une C; Ramírez V; González MI; Ramírez JA; de Mascarel A; Barahona R; Salas-Aguilar R; Páez R; Avendaño G; Avalos A; Broutet N; Mégraud F
    Clin Exp Med; 2006 Jun; 6(2):72-8. PubMed ID: 16820994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population.
    Agréus L; Storskrubb T; Aro P; Ronkainen J; Talley NJ; Sipponen P
    Scand J Gastroenterol; 2009; 44(5):564-70. PubMed ID: 19263272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica.
    Con SA; Con-Wong R; Con-Chin GR; Con-Chin VG; Takeuchi H; Valerín AL; Echandi G; Mena F; Brenes F; Yasuda N; Araki K; Sugiura T
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2631-6. PubMed ID: 18086767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.
    Dinis-Ribeiro M; da Costa-Pereira A; Lopes C; Barbosa J; Guilherme M; Moreira-Dias L; Lomba-Viana H; Silva R; Abreu N; Lomba-Viana R
    Neoplasia; 2004; 6(5):449-56. PubMed ID: 15548353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer.
    Pimanov SI; Makarenko EV; Voropaeva AV; Matveenko ME; Voropaev EV
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1666-71. PubMed ID: 17559360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis.
    Kim EH; Kang H; Park CH; Choi HS; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
    Dig Liver Dis; 2015 Aug; 47(8):663-8. PubMed ID: 26077884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pepsinogen and gastrin in the noninvasive diagnosis of gastric atrophy. A case-control study in Peruvian population].
    Colarossi A; Inga R; Prochazka R; Reyes U; Bussalleu A; Barúa RL
    Rev Gastroenterol Peru; 2011; 31(2):110-5. PubMed ID: 21836650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies.
    Al-Assi MT; Miki K; Walsh JH; Graham DP; Asaka M; Graham DY
    Am J Gastroenterol; 1999 Sep; 94(9):2367-72. PubMed ID: 10483993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population.
    Zhang L; Blot WJ; You WC; Chang YS; Kneller RW; Jin ML; Li JY; Zhao L; Liu WD; Zhang JS; Ma JL; Samloff IM; Correa P; Blaser MJ; Xu GW; Fraumeni JF
    Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):627-30. PubMed ID: 8824365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age and severity of mucosal lesions influence the performance of serologic markers in Helicobacter pylori-associated gastroduodenal pathologies.
    Camorlinga-Ponce M; Flores-Luna L; Lazcano-Ponce E; Herrero R; Bernal-Sahagún F; Abdo-Francis JM; Aguirre-García J; Muñoz N; Torres J
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2498-504. PubMed ID: 18768521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis.
    Sitas F; Smallwood R; Jewell D; Millard PR; Newell DG; Meuwissen SG; Moses S; Zwiers A; Forman D
    Cancer Epidemiol Biomarkers Prev; 1993; 2(2):119-23. PubMed ID: 8467246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer.
    You WC; Blot WJ; Zhang L; Kneller RW; Li JY; Jin ML; Chang YS; Zeng XR; Zhao L; Fraumeni JF
    Cancer Epidemiol Biomarkers Prev; 1993; 2(2):113-7. PubMed ID: 8467245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care.
    Germaná B; Di Mario F; Cavallaro LG; Moussa AM; Lecis P; Liatoupolou S; Comparato G; Carloni C; Bertiato G; Battiestel M; Papa N; Aragona G; Cavestro GM; Iori V; Merli R; Bertolini S; Caruana P; Franzé A
    Dig Liver Dis; 2005 Jul; 37(7):501-8. PubMed ID: 15975537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma.
    Sugiu K; Kamada T; Ito M; Kaya S; Tanaka A; Kusunoki H; Hata J; Haruma K
    Dig Liver Dis; 2006 May; 38(5):303-7. PubMed ID: 16549394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic values of serum levels of pepsinogens and gastrin-17 for screening gastritis and gastric cancer in a high risk area in northern Iran.
    Nejadi-Kelarijani F; Roshandel G; Semnani S; Ahmadi A; Faghani B; Besharat S; Akhavan-Tabib A; Amiriani T
    Asian Pac J Cancer Prev; 2014; 15(17):7433-6. PubMed ID: 25227854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen.
    Wu KC; Li HT; Qiao TD; Li CN; Ji WS; Tian FQ; Wang X; Wang BL; Miao JY; Ding J; Fan DM
    Chin J Dig Dis; 2004; 5(1):22-7. PubMed ID: 15612668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of serum pepsinogen I , II and osteopontin co-detection in gastric cancer screening].
    Gong YH; Sun LP; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):691-3. PubMed ID: 17274377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Potentialities of a serological method in diagnosis of atrophic gastritis].
    Pimenov SI; Makarenko EV
    Ter Arkh; 2008; 80(2):15-21. PubMed ID: 18372589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.